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Abstract
Purpose Ischemic stroke is a frequent pathology with high
rate of recurrence and significant morbidity and mortality.
There are several causes of stroke, affecting prognosis,
outcomes, and management, but in many cases, the etiology
remains undetermined. We hypothesized that atrial fibrilla-
tion was involved in this pathology but underdiagnosed by
standard methods. The aim of the study was to determine
the incidence of atrial fibrillation in cryptogenic ischemic
stroke by using continuous monitoring of the heart rate over
several months. The secondary objective was to test the
value of atrial vulnerability assessment in predicting
spontaneous atrial fibrillation.
Methods and results We prospectively enrolled 24 patients
under 75 years of age, 15 men and 9 women of mean age
49 years, who within the last 4 months had experienced
cryptogenic stroke diagnosed by clinical presentation and
brain imaging and presumed to be of cardioembolic mecha-
nism. All causes of stroke were excluded by normal 12-lead
ECG, 24-h Holter monitoring, echocardiography, cervical
Doppler, hematological, and inflammatory tests. All patients
underwent electrophysiological study. Of the patients, 37.5%
had latent atrial vulnerability, and 33.3% had inducible
sustained arrhythmia. Patients were secondarily implanted
with an implantable loop recorder to look for spontaneous
atrial fibrillation over a mean follow-up interval of
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14.5 months. No sustained arrhythmia was found. Only one
patient had non-significant episodes of atrial fibrillation.
Conclusion In this study, symptomatic atrial fibrillation or
AF with fast ventricular rate has not been demonstrated by
the implantable loop recorder in patients under 75 years
with unexplained cerebral ischemia. The use of this device
should not be generalized in the systematic evaluation of
these patients. In addition, this study attests that the
assessment of atrial vulnerability is poor at predicting
spontaneous arrhythmia in such patients.
Keywords Atrial fibrillation . Stroke . Cardioembolic .
Atrial vulnerability . Implantable loop recorder
1 Introduction
Ischemic stroke (IS) is a frequent pathology whose incidence
sharply increases with age, 0.1/1,000 inhabitants per year
below the age of 45 and up to 10/1,000 over 75 years of age in
France [1]. It is the third cause of death and is responsible for
50% of disabling conditions in survivors [2] in industrialized
countries. The causes are various, but events of undeter-
mined etiology are frequent [3]. We suggested that a
significant proportion of these unexplained strokes or
transient ischemic attacks (TIA) could be due to undiagnosed
atrial fibrillation (AF). AF is a common cause of embolism,
but it can be difficult to identify due to asymptomatic or
paroxysmal episodes [4, 5]. Some authors have advocated
studying the atrial vulnerability (AV) to arrhythmias to
explain the mechanism of cryptogenic IS [6, 7]. In the
presence of a low atrial vulnerability index or induction of
AF, oral anticoagulation and antiarrhythmic therapy were
recommended by these same authors, but the predictive
value of this electrophysiological method for spontaneous
AF remains controversial [8, 9]. We therefore aimed to
document spontaneous AF in a population of patients with
unexplained IS/TIA, using invasive continuous cardiac
monitoring by means of an implantable loop recorder
(ILR). This device, widely used for diagnosis of unexplained
syncope [10], has proven effective in detecting paroxysmal
arrhythmias [11, 12]. We also wanted to correlate the results
of continuous electrocardiogram monitoring with those of
AV electrophysiological studies in order to test the value of
this method for predicting spontaneous AF.
2 Patients and methods
This is a prospective multicenter study whose aim was to
determine the prevalence of AF in patients under 75 years
of age with a history of IS or TIA of undetermined cause
after complete evaluation.
2.1 Patient enrollment
The enrollment took place in the cardiology or neurology
units of four hospitals in France. Patients were to be
between 18 and 75 years old, have a history of cerebral
ischemia within 4 months before inclusion, and have
recovered neurological status allowing good autonomy
(Rankin score between 0 and 2 at inclusion [13]). The
neurological features of each patient were reviewed by the
referent neurologist of the study, who validated the diagnosis
of IS/TIA from anamnesis, clinical presentation, and the
results of brain imaging. All patients underwent at least
cerebral CT or MRI, or both, depending on the equipment of
the recruiting centre. Cerebral hemorrhage was excluded.
Undetermined origin was ascertained by negative evaluation
requiring ancillary tests performed in all patients to exclude
the following conditions:
– Ipsilateral carotid atherosclerotic stenosis >70%, vertebral
or carotid dissection with cervical Doppler-echography or
angio-MR.
– Documented atrial fibrillation, with a 12-lead electro-
cardiogram and 24-h Holter monitoring.
– Intracardiac thrombus or any other cause of cardiac
embolism, with transthoracic (n=24/24) and trans-
esophageal echocardiography (n=22/24).
– Vascular malformation, by means of cerebral CT, MRI
or angio-MRI if necessary.
– Hypercoagulable states, hematological disorders, and
inflammatory diseases, with biological tests carried out
at least 2 months after stroke: prothrombin ratio,
activated partial thromboplastin time, C and S proteins,
antithrombin, mutation in Factor V Leiden gene,
circulating anticoagulants, antiphospholipid and anti-
ß2gp1 antibodies, homocysteinemia, erythrocyte sedi-
mentation rate, and C-reactive protein.
A history of documented cardiac arrhythmias and
ineffectively controlled pre-stroke hypertension (defined
by systolic blood pressure >140 mmHg or diastolic
>90 mmHg) were also exclusion criteria.
Informed consent was signed by all patients before
inclusion.
The study protocol resulted from a regional 2003
Hospital Program of Clinical Research promoted by the
University Hospital of Tours and received approval from
the Institutional Ethics Committee (CCPPRB of Tours) on
June 29, 2004.
2.2 Study of atrial vulnerability
The electrophysiological study was performed using low-
molecular-weight heparin for effective anticoagulation.
Two quadripolar electrode catheters (10-mm interelectrode
102 J Interv Card Electrophysiol (2010) 28:101–107
distance, USCI, Bard) were placed in the right cardiac
cavities via catheterization of the right femoral vein under
local anesthesia. One quadripolar electrode was positioned
in the high right atrium (HRA) in the sinus node area; the
other one was placed in the low right atrium (LRA) near the
atrioventricular node. Pacing was performed with a pro-
grammable stimulator (Biotronik UHS, Germany) which
delivered rectangular pulses of 2-ms duration at twice the
diastolic threshold. The study was carried out in three stages:
– Measurement of basic conduction intervals and deter-
mination of the Wenckebach point of the atrioventric-
ular node.
– Determination of the right atrium refractory periods
(RP) and the duration of the atrial electrogram. RPs
were determined by means of an extrastimulus (S2)
delivered at three different constant pacing rates 100,
120, 150 bpm. Effective RP was defined as the longest
attainable S1–S2 interval that did not produce an atrial
electrogram. Finally, we measured the duration of the
atrial electrogram (A2) following S2 at a pacing rate of
100 bpm. Latent vulnerability index (LVI) was defined
as the ratio between high right atrium effective
refractory period (ERP) and A2 duration at a pacing
rate of 100 bpm [7, 14].
– Assessment of the inducibility of atrial arrhythmia was
performed by programmed atrial stimulation with up to
three extrastimuli (S2, S3, S4) at constant pacing rates
of 100, 120, and 150 bpm at two different stimulation
sites: HRA and LRA.
Latent atrial vulnerability was defined as LVI <2.5, and
atrial inducibility as induction of sustained atrial arrhythmia
lasting >60 s [7, 14].
2.3 Implantation of Holter monitor
The ILR (Medtronic™ Reveal® Plus ILR 9526, Med-
tronic Inc., Minneapolis, USA) is a small single-use
device fitted with two sensing electrodes. It can record
the heartbeat loop for 14 months. When interrogated
transcutaneously, it can return recorded rhythmic events.
The ILR was implanted subcutaneously under local
anesthesia and antibiotic prophylaxis in the left pectoral
region. The device was programmed similarly for all
patients before their discharge:
– Semi-automatic activation mode.
– Recording of 13 automatic events and 1 event by
patient activation. Patients were provided with an
activator at the time of device implantation.
– The criteria for automatic recording were bradycardia
<30 bpm or pause >3 s, tachycardia >165 bpm for
more than 32 complexes.
Patients were instructed to activate the device in case of
palpitations, syncope, or recurrence of IS/TIA.
2.4 Treatment
All patients received antiplatelet therapy, aspirin 300 mg/day,
or clopidogrel 75 mg/day.
2.5 Patient follow-up
Patients underwent examination and 12-lead ECG every
4 months, performed by the investigator of the recruiting
hospital. Interrogation of the ILR was carried out at each
visit and stored for review by the principal investigator. AF
was considered to have occurred when normal sinus rhythm
was replaced by irregular tachycardia lasting more than 30 s
with no visible P wave or with unorganized F wavelets of
AF. In this case, antiarrhythmic therapy was prescribed
according to the habitual procedure of each investigator,
and antiplatelet therapy was replaced by oral anticoagula-
tion treatment with a target International Normalized Ratio
(INR) between two and three. In the event of a serious issue
(recurrence of stroke, syncope, death), the nearest investi-
gator hospital was contacted for interrogation of the ILR.
The study ended for a patient when sustained AF was
documented by the monitor or after the monitoring period
of 14 months with the device's explantation (end of battery
life defined by the manufacturer of the Reveal Plus® ILR
9526).
3 Results
Twenty-four patients were included, 15 men and 9 women,
from 19 to 74 years old, mean age 48.8±13.6 years. The
subjects' characteristics are summarized in Table 1. Al-
though 50 patients were provided, inclusions were stopped
prematurely because of negative results.
Table 1 Characteristics of subjects (n=24)
Male n (%) 15 (62.5)
Age (years) (mean±SD) 49±13.6
<50 years n (%) 14 (58.3)
Diabetes mellitus 0
Hypertension n (%) 7 (29.2)
Dyslipidemia n (%) 8 (33.3)
Active tobacco use n (%) 10 (41.7)
Overweight (BMI>27.5) n (%) 4 (16.7)
Vascular ischemic hereditary n (%) 5 (20.8)
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3.1 Neurological features
Of the 24 enrolled patients, 3 (12.5%) experienced TIA
with symptoms lasting less than 1 h (and normal brain
MRI), and 21 (87.5%) experienced cerebral infarction; one of
them remained with neurological sequelae (Rankin score=2),
symptoms were fully reversible in all the others. The clinical
presentation consisted of lateralized motor deficit or aphasia
in 75% of the cases, with or without sensory symptoms. There
was one case of isolated retinal event. All patients underwent
at least one brain imaging, cerebral CT (n=17) or MRI (n=
15) or both (n=8), and four patients had an angio-MRI
performed. The topography of cerebral ischemia is summa-
rized in Table 2. The most common types of infarcts were
superficial middle cerebral artery territory infarcts (58.3%).
One in three patients showed at least two concomitant
ischemic locations, lesions were bilateral in 20.8% of cases.
Brain MRI revealed images of past infarcts in four cases
(26.7%).
3.2 Electrophysiological study
The results are shown in Table 3. We observed 18 patients
with supraventricular arrhythmias, 15 AF, 1 common
flutter, and 2 other atrial tachycardias. Eight of these,
termed “inducible” patients, experienced sustained arrhyth-
mia, lasting more than 60 s. The LVI was calculated
whenever possible with the formula described above. It
could not be calculated in four cases because of the
impossibility of measuring RP or A2 duration due to early
onset of sustained arrhythmia. Latent AV was found in nine
patients (37.5%), among whom, three were inducible.
3.3 Implantable ECG monitor
The mean time lapse from cerebral accident to initiation of
cardiac rhythm monitoring, i.e., implantation of the ILR,
was 3±1.1 months. The mean monitoring duration was
14.5 months. There was no loss of follow-up. There was no
recurrence of stroke, no episode of syncope or palpitation
was reported, and all electrocardiograms were in sinus
rhythm. Through ILR interrogation, we found short AF
episodes <30 s in one patient (4.2%), detected by automatic
record, with a ventricular rate exceeding 200 bpm. This
patient was not inducible through programmed atrial
stimulation despite a positive latent vulnerability (LVI=
1.5). No significant AF episode or any other sustained
arrhythmia was identified, either in inducible patients or in
the others. Moreover, no significant sinus pause or sinus
bradycardia was observed that could have led to a diagnosis
of bradycardia–tachycardia syndrome.
Table 3 Electrophysiological study results (n=24)
Mean±SD Min Max Number (%)
AH interval (ms) 83±22.4 15 125
HV interval (ms) 43±9.38 30 65
Wenckebach point of AV node (bpm) 162±35.2 110 230
HRA ERP (ms) 234±37.1 180 290
A2 duration (ms) 85±26.4 50 140
LVI (n=20) 2.9±1.02 1.5 5.6
LVI<2.5 9 (37.5)
Inducibility of atrial arrhythmia (including AF, flutter, and other atrial tachycardias) 18 (75.0)
0–30 s 8 (33.3)
30–59 s 2 (8.3)
1–5 min 5 (20.8)
>5 min 3 (12.5)
Table 2 Neurological features: topography of cerebral infarcts (n=
24)
Topography of infarcts Number Percentage
Middle cerebral artery (MCA) territory 20 83.3
Superficial MCA 14 58.3
Deep MCA 3 12.5
Global MCA 3 12.5
Vertebrobasilar territory 7 29.2
Posterior cerebral artery territory 3 12.5
Cerebellum 4 16.7
Multiple lesions 8 33.3
Bilateral 5 20.8
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4 Discussion
4.1 Atrial fibrillation and stroke
Because of the high recurrence rate of ischemic cerebral
accidents, secondary prevention after a first-ever event is
essential. Despite an extensive evaluation, no determined
etiology is found in one third to half of all cases, especially
in young subjects [15]. It is currently estimated that 30% of
IS have a cardioembolic substrate, about half of which are
due to AF [3]. AF is a very common arrhythmia whose
prevalence increases with age up to 10% after the age of 75
versus 0.4% in the general population [16]. Arterial
embolism is a frequent complication of AF, with a risk of
5% to 10% per year, especially in subjects with cardiovas-
cular risk factors (hypertension, diabetes, heart failure) [17,
18]. Identifying a potential cardiac source of embolism is of
critical importance in the etiological workup of IS because
of therapeutic and prognostic implications. Epidemiological
studies have shown a poorer prognosis for IS/TIA of
cardioembolic origin than from other causes, especially
those due to AF [3, 19, 20]. If AF is identified as the cause
of a first-ever cerebral infarction, anticoagulation therapy
significantly reduces the recurrence rate as compared with
antiplatelet therapy and dramatically improves these
patients' prognosis [17, 21–23]. Unfortunately, AF is
difficult to detect. The yield is low for 12-lead ECGs, as
well as for 24- to 72-h Holter monitoring (2% to 5%) [24,
25]. Preliminary studies suggested that extending the
duration of heart rate monitoring would increase the
probability of detecting paroxysmal AF [25–27]. The ILR
offers the benefit of continuously monitoring cardiac
rhythm over several months.
In our study, cerebral ischemic accidents were suspected
to be of cardioembolic mechanism, as evidenced by the
frequency of multiple, especially bilateral lesions. The
exclusion of uncontrolled pre-stroke hypertension limited
possible confusion with lacunar events. Nevertheless,
among the 24 enrolled patients, AF was detected as a
potential cause of stroke in only one patient. In a recent
study by Tayal et al. [28] on patients with cryptogenic IS/
TIA, the authors found a higher detection rate of AF using
21-day monitoring with mobile cardiac outpatient teleme-
try, 5.3% of AF >30 s and 23% of short episodes <30 s. We
can assume that the difference is due to patient selection
and time of initiation of the monitoring. In the Tayal study,
the patients were at higher risk of AF because they were
older (mean age 66±11 versus 49±13 years in our study),
and the prevalence of diabetes was high. Age and diabetes
mellitus are well-known risk factors for AF [16, 29]. It is to
be noticed that diabetics were absent from our population.
In the Tayal study, rhythm monitoring after index event was
initiated earlier than in ours (mean 20 days versus
3 months). In their work, the majority of AF were
diagnosed within the first days of monitoring (mean 7 days,
range 2–19). However, early transient AF has been reported
after acute stroke only as a consequence of the stroke [30],
which led us purposely to choose to delay the initiation of
monitoring in order to avoid confusion as to the responsi-
bility of the stroke for the onset of paroxysmal arrhythmia.
4.2 Atrial vulnerability
The aim of the AV study was to identify subjects with a
high risk of atrial arrhythmia. It has been shown that
patients with documented AF more often have a low LVI
and are more easily inducible than patients without AF [8,
15]. The predictive value of these findings has been studied
in different clinical situations. Some authors have described
similar electrophysiological abnormalities in patients with
paroxysmal AF and in patients with unexplained ischemic
stroke [8, 31]. However, the correlation between the
presence of an arrhythmogenic substrate and the occurrence
of spontaneous AF has not been proven. In previous series, the
percentage of inducible sustained AF in patients with
cryptogenic IS was 50% to 65% [6, 8]. We also found a high
rate of inducible sustained atrial arrhythmias (33.3%) and a
high rate of latent AV (37.5%), whereas no spontaneous
sustained asymptomatic AF or AF with fast ventricular
response was documented over a period of 14 months.
Moreover, the only patient who experienced short episodes
of spontaneous AF was not inducible by programmed atrial
stimulation. For the first time, continuous monitoring in a
prospective study has made it possible to confirm the
irrelevance of electrophysiological study in the etiological
workup of IS/TIA, because neither low LVI nor atrial
arrhythmia inducibility was predictive of spontaneous AF.
4.3 Limitations of the study
This study has some limitations. Firstly, the duration of the
study was shortened by the device's limited battery life.
Rhythm monitoring was thus limited to 14 months, which
is brief compared to the period of stroke recurrences. As
epidemiological data in the literature reveal that the risk of
recurrent stroke is high in the early phase after a first-ever
event and remains high for several years thereafter [19, 32,
33], there is little prospect that the new generation of ILR
with a prolonged battery life (more than 36 months) would
be more informative. A second limitation arose from the
drawbacks of the ILR device itself. The algorithm required
32 consecutive beats at 165 bpm to recognize a rhythm
disturbance as an AF episode. It was consequently
programmed to record AF with rapid ventricular response,
making it likely that a number of non-rapid episodes may
have been missed. Regarding self-activation, previous
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studies have showed the inability of some patients to
operate loop recorders properly [11]. This was not a
problem in our study because no triggering symptom was
experienced resulting from patients' failure to activate. In
the future, the ILR will be designed to record atrial activity
more accurately in order to diagnose AF with lower
ventricular response. The latest model of ILR (Reveal®
XT, Medtronic Inc., Minneapolis, USA) seems to meet this
objective, but the device is not yet available in France.
Finally, it might be objected that a major limitation lies
in the limited size of the study, given the low number of 24
subjects included. Patients' inclusion was hampered by
difficulties in getting them to accept the protocol, particu-
larly because of the invasiveness of procedures. Inclusion
was limited to 24 patients for reasons of ethical consid-
erations and cost effectiveness on the grounds that the absence
of sustained AF in this population made the diagnostic
method uneconomical. We suspect that the efficacy of the
method could be improved by applying it to a selected
population at higher risk of AF, specifically including more
diabetics and older patients.
5 Conclusion
This study suggests that symptomatic atrial fibrillation or AF
with fast ventricular rate is not a frequent pathology in patients
under the age of 75 with unexplained ischemic stroke. These
results do not plead for generalizing the use of an implantable
loop recorder in the systematic evaluation of these patients.
Further studies are needed to test the efficacy and cost
effectiveness of the method in a selected population with a
higher risk of atrial fibrillation, using an updated device that
more accurately diagnoses AF with low ventricular response.
Finally, this study asserts that the electrophysiological study of
atrial vulnerability is poor at predicting spontaneous atrial
fibrillation after cryptogenic cerebral ischemia.
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